Docetaxel Baxter 01
Chemical structure of docetaxel, the active ingredient in Docetaxel injection, solution 10 mg/mL by Baxter Healthcare Corporation.*
Docetaxel Injection, Solution
Product Images NDC 43066-001
14 FDA label images from Baxter Healthcare Corporation · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 43066-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Baxter Healthcare Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Docetaxel Baxter 02
A line graph showing disease-free survival (DFS) probability over time in months. Two curves represent different treatment groups labeled TAC and FAC, tracking DFS probability percentages from 0 to 70 months.*
Docetaxel Baxter 03
A line graph comparing survival probability percentages over survival time in months for two treatment groups labeled TAC and FAC, showing a gradual decline in survival probability over approximately 72 months.*
Docetaxel Baxter 04
A survival curve chart depicting overall survival probability over time in months. It compares two groups labeled T75 and BSC, showing cumulative probability on the vertical axis and survival time in months on the horizontal axis. A log-rank p-value of 0.010 is noted, indicating statistical analysis of the difference between the groups.*
Docetaxel Baxter 05
A survival curve graph depicting cumulative probability versus survival time in months. The chart compares two curves labeled T75 and V1, showing overall survival over a period of up to 21 months. The graph includes a log-rank p-value of 0.13.*
Docetaxel Baxter 06
A survival probability graph displaying two plotted lines labeled T75 q3w and M q3w. The x-axis represents survival time in months (0 to 30), and the y-axis shows survival probability (0.1 to 1.0). The chart compares survival over time for two different groups or treatments.*
Docetaxel Baxter 07
A Kaplan-Meier survival curve showing probability (%) on the y-axis and time in months on the x-axis. Two treatment groups are compared: TCF (solid line) and CF (dashed line), depicting survival probabilities over a 24-month period.*
Docetaxel Baxter 08
A survival probability Kaplan-Meier curve graph displaying survival time in months on the x-axis and survival probability percentage on the y-axis. Two groups are represented: TCF with a solid line and CF with a dashed line, comparing their survival outcomes over a period of up to 36 months.*
Docetaxel Baxter 09
A line graph depicting Progression Free Survival (PFS) probability over time in months. Two treatment groups, TPF and PF, are compared, with the graph showing how PFS probability decreases as time progresses up to 42 months.*
Docetaxel Baxter 10
A survival probability Kaplan-Meier curve chart showing survival time in months on the x-axis and survival probability percentage on the y-axis. Two groups are depicted: TPF and PF, with TPF consistently showing higher survival probabilities throughout the observed period up to 72 months.*
Docetaxel Baxter 11
A Kaplan-Meier survival curve graph depicting survival probability (%) over time in months. It compares two groups labeled TPF (n=255) with a solid line and PF (n=246) with a dashed line. The x-axis represents survival time up to 72 months; the y-axis shows survival probability from 0 to 100%. Below the graph is a table showing the number of patients at risk at various time points for each group.*
Docetaxel Baxter 12
Docetaxel Injection 20 mg/2 mL (10 mg/mL) injection solution carton from Baxter Healthcare Corporation. The label states the product is for intravenous infusion only and contains warnings about cytotoxicity. It includes storage instructions, manufacturer and distributor information, and directions to refer to the package insert for dosing and handling details. The package contains two milliliters of solution in a multiple-dose vial form.*
Docetaxel Baxter 13
Docetaxel Injection 80 mg/8 mL (10 mg/mL) intravenous solution label carton. Manufactured by FAREVA Unterach GmbH and distributed by Baxter Healthcare Corporation. Contains warnings for cytotoxic use and storage instructions to protect from light and keep between 2° and 25°C. The label indicates the product is ready to add to infusion solution and specifies concentration check prior to preparation.*
Docetaxel Baxter 14
Packaging label for Docetaxel Injection 160 mg/16 mL (10 mg/mL) solution for intravenous infusion. The label shows it is a multiple-dose vial, manufactured by FAREVA Unterach GmbH, Austria, and distributed by Baxter Healthcare Corporation, USA. It includes warnings about cytotoxicity, instructions to check concentration prior to preparation, and storage conditions. The label has barcodes and prominently displays the Baxter logo.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
